Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

TB-500 peptide icon, one bubble per amino acidTB-5007 residuesLKKTETQEach bubble = one amino acid. Size = residue mass. Color = chemical class.

TB-500

Beginner tier: 2 mg, 2x/week · 6w on / 2w off · community consensus

5 h half-life (estimated)·Injection

Also known as: TB-500, TB500, Ac-LKKTETQ

Get an alert when FDA rules on TB-500

Follow every legal or FDA change, TB-500 included. By default, alerts come as one weekly push that names the peptides.

Reepithelialization up 42% at day 4 and 61% at day 7 in preclinical wound models (Malinda et al.)[1]. TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) of the 43-amino acid thymosin beta-4 protein. It promotes angiogenesis, reduces fibrosis, and accelerates cell migration to injury sites. No published study has given the fragment itself to people. Two published IV phase 1 trials, Ruff 2010 [5] and Wang 2021 [2], tested the full parent protein. Community evidence across 500+ Reddit threads tells a different story: consistent reports of tendon, ligament, and muscle recovery within 3 to 4 weeks of loading. One catch: no FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. FDA's Category 2 page (current as of April 22, 2026) lists TB-500 as withdrawn by its nominators, and PCAC discussed it on July 23, 2026.

What Is TB-500?

Seven amino acids. That is all TB-500 is. Acetylated leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, pulled from positions 17 through 23 of the 43-amino-acid thymosin beta-4 protein. CAS number 885340-08-9, molecular weight 889.0 Da.

The mechanism is well characterized in animals. TB-500 binds monomeric G-actin, sequestering free actin subunits and remodeling the cytoskeleton so that endothelial and immune cells migrate faster to damaged tissue. It upregulates VEGF 2.5 to 3.8-fold. Malinda and colleagues confirmed that thymosin beta-4 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls in rat full-thickness skin wounds [1]. It also suppresses myofibroblast differentiation, which reduces scar formation.

What makes TB-500 unusual is systemic distribution. You don't need to inject near the injury. Subcutaneous injection in the abdomen reaches a torn rotator cuff the same way it reaches a strained hamstring. Community users have validated this property thousands of times over.

No published study has given the TB-500 fragment to people. FDA's briefing for the July 2026 compounding advisory committee meeting found no clinical studies or human exposure data for it by any route. A 2024 metabolite study by Rahaman and colleagues added a wrinkle: the parent compound showed no wound-healing activity in vitro. The metabolite Ac-LKKTE was the active species. That finding has not changed community dosing practices, but it raises questions about mechanism attribution.

Community confidence (4.1/5 sentiment, 500+ r/Peptides threads) sits well ahead of the formal evidence base. TB-500 was on the FDA Category 2 list from 2024 until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed it on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. All current supply is unregulated gray-market product.

How TB-500 Works

TB-500 works through actin dynamics. The peptide binds to monomeric G-actin and sequesters free actin subunits, shifting the balance of cytoskeletal assembly inside cells. When cells need to migrate to an injury site, they depend on rapid actin polymerization at the leading edge. TB-500 regulates that process.

This actin-sequestering activity drives two downstream effects. The first is angiogenesis. TB-500 upregulates vascular endothelial growth factor (VEGF) 2.5 to 3.8-fold in preclinical models. More capillaries at the injury site mean better oxygen delivery and faster tissue remodeling.

The second downstream effect is anti-fibrotic. TB-500 inhibits myofibroblast differentiation, the process responsible for excessive scar tissue formation. In preclinical wound models, this translated to cleaner healing with less fibrosis.

Malinda and colleagues published the foundational wound healing data in 1999 [1]. Thymosin beta-4 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls. Bock-Marquette and colleagues confirmed cardioprotective effects after myocardial infarction in animal models [3]. A 2026 review in Cureus (PMC12753158) placed TB-500 among the most promising orthopedic peptides based on preclinical data quality.

One important caveat: a 2024 metabolite study found that the TB-500 parent compound had no wound-healing activity in vitro. The metabolite Ac-LKKTE was the active species. In-vivo activity may depend on metabolic conversion.

TB-500 Benefits

  • TB-500 benefits center on systemic tissue repair, angiogenesis, and anti-fibrotic activity.
  • Systemic healing without site-specific injection. TB-500 distributes throughout the body after subcutaneous injection. Community users consistently confirm that injection location does not affect results for distant injuries.
  • Angiogenesis with VEGF upregulation of 2.5 to 3.8-fold in preclinical models. New capillary formation at injury sites improves oxygen and nutrient delivery during repair.
  • Anti-fibrotic activity through myofibroblast suppression. TB-500 reduces scar tissue formation during healing, which translates to better tissue quality and flexibility in recovered areas.
  • Soft tissue recovery for tendons, ligaments, and muscle tears. Community reports across 500+ threads consistently describe pain reduction and improved range of motion by weeks 3 to 4 of loading.
  • Paired with BPC-157 in the "Wolverine Stack," the most popular healing combination in the peptide community. BPC-157 handles local repair near the injection site; TB-500 provides systemic angiogenic support. In a 2026 rat Achilles study [4], TB-500 alone improved tendon strength, and adding BPC-157 gave no extra benefit.

TB-500: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 12 key studies·Preclinical

Strong preclinical evidence for thymosin beta-4 and its active fragment in wound healing, angiogenesis (VEGF upregulation 2.5–3.8×), and actin-mediated cell migration.

Dosing studied: 4–5 mg/week (2–2.5 mg 2×/week) loading for 4–6 weeks; maintenance at 1,000-2,000 mcg once weekly (community reports): derived entirely from community consensus extrapolated from preclinical data; no human dose-finding study completed for the TB-500 fragment specifically
Read the evidence (key study, limitations)

Fragment-specific human data is absent: both published phase 1 trials, Ruff 2010 [5] and Wang 2021 [2], used full 43-AA thymosin beta-4, not the 7-AA TB-500 fragment. A 2024 metabolite study (Rahaman et al., J Chromatogr B) found the TB-500 parent compound had no wound-healing activity in vitro: metabolite Ac-LKKTE was the active species, introducing uncertainty about in vivo mechanism attribution. FDA's briefing for the July 2026 PCAC meeting found no clinical studies or human exposure data for TB-500 by any route.

Key Study

Malinda et al. 1999, "Thymosin beta 4 accelerates wound healing," J Invest Dermatol. PMID 10469335: full TB4 increased reepithelialization 42% at day 4 and 61% at day 7 vs. controls in rat full-thickness skin wounds; foundational study establishing the wound healing mechanistic basis (note: tested full TB4, not TB-500 fragment)

Limitations

No human trial of the TB-500 fragment has been published at any phase. Two published IV phase 1 trials, Ruff 2010 (PMID 20536472) and Wang 2021 (PMID 34346165), tested the full parent protein, 43-AA thymosin beta-4: PK and safety data cannot be directly applied to the 7-AA fragment. 2024 metabolite study suggests the parent peptide may be inactive in vitro; in-vivo activity may depend on metabolic conversion to Ac-LKKTE. No published human PK characterization for TB-500 fragment. Long-term safety unknown. Theoretical oncogenic risk from pro-angiogenic mechanism is unresolved. No rodent-validated human dose range.

Community Experience
Strong
4.1/5
Based on ~500+ r/Peptides threads

One of the most trusted healing peptides in the research community (4.1/5 sentiment, 500+ r/Peptides threads).

Community dosing: 4–5 mg/week loading (2–2.5 mg 2×/week for 4–6 weeks), then maintenance at 1,000-2,000 mcg once weekly (community reports); conservative start: 2 mg 2×/week; aggressive acute injury: up to 10 mg/week for 2–4 weeks maximum
Read the reports (what users report 5, common issues 5)

Standard loading/maintenance structure is well-established and consistently reproduced across community reports. Most valued for tendon, ligament, and muscle injury recovery. Key advantage repeatedly cited: systemic action means no need to inject at the injury site. Main concerns are cost and sourcing quality variability under current FDA restrictions.

What users report (5)
  • Soft tissue healing: tendons, ligaments, and muscle tears (most commonly reported use)
  • Systemic distribution: injection site irrelevant to injury location
  • Pain reduction and improved range of motion, typically noticeable weeks 3–4 of loading
  • Reduced inflammation and fibrosis at chronic injury sites
  • Complementary pairing with BPC-157 ("Wolverine Stack") considered the top healing peptide combination in the community
Common issues (5)
  • High cost: $150–$450/month depending on protocol; most commonly cited barrier to use
  • Product quality inconsistency: contamination and mislabeling documented; endotoxin risk from unregulated gray-market manufacturers
  • Transient fatigue and lethargy during loading phase (weeks 1–2): common, usually self-resolving
  • Underdosing is the #1 reported reason for disappointing results: skipping loading phase or going straight to maintenance dose
  • Continuing the injurious activity during the protocol frequently cited as counterproductive
Partially Aligned

Community protocols are consistent with the preclinical mechanistic data (angiogenesis, actin sequestration, systemic distribution). However, the 2024 metabolite study challenges direct attribution of wound-healing activity to the parent peptide, and no human RCT for the fragment exists. Community confidence significantly exceeds what the fragment-specific evidence base strictly supports. The systemic dosing approach (injection site irrelevance) is mechanistically well-grounded.

TB-500 Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner2 mg
2x/weekTrack
Moderate2.5 mg
2x/weekTrack
Aggressive5 mg
2x/weekTrack
Note:

All TB-500 dosing is community-driven. No human dose-finding study exists for the fragment. Beginner: 2000 mcg (2 mg) twice weekly. Moderate: 2500 mcg (2.5 mg) twice weekly. Aggressive: 5000 mcg (5 mg) twice weekly.

Reconstitution math for a 5 mg vial with 1 mL bacteriostatic water: concentration is 5000 mcg per mL. Each 10 units on a 100-unit insulin syringe equals 500 mcg. So 2000 mcg (beginner dose) is 40 units. For a 10 mg vial with 1 mL BAC water: 10,000 mcg per mL, meaning 20 units for 2000 mcg.

The loading phase matters more than anything else. Skipping it is the single most common reason for disappointing results. You need 2 injections per week for at least 4 to 6 weeks to build adequate tissue-level concentrations. Going straight to once-weekly maintenance is an underdose.

Don't train through the injury during a TB-500 protocol. The community figured this out quickly: TB-500 accelerates repair, but it doesn't protect against re-injury from continued loading of the damaged tissue. Relative rest of the injured structure speeds outcomes.

Injection site does not need to be near the injury. Abdomen or thigh, alternating sides.

Cycling Protocol

On Period
6 weeks
Off Period
2 weeks

Loading phase: full dose 2x/week for 4-6 weeks. Then maintenance: 1,000-2,000 mcg once weekly (community reports). Repeat loading if needed for new injuries.

Calculate your TB-500 dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

TB-500 Protocols by Goal

beginnerCommunity6–12 weeks total (6-week loading + up to 6-week maintenance)
Loading
Wk 1–6
2000 mcg · 2×/week (e.g., Mon/Thu) · Subcutaneous
Maintenance
Wk 7–12
1000–2000 mcg · 1×/week · Subcutaneous

Expected: Noticeable pain reduction and improved range of motion by weeks 3–4; significant soft tissue improvement by end of loading phase; full healing of moderate injuries possible by week 12

Monitor: Monitor for injection site reactions, fatigue, and headache during loading phase. These are common and typically self-resolve by week 3. Fever above 100.4°F or skin rash requires stopping and medical evaluation.

How to Inject TB-500

  1. 1
    Reconstitute: add 1 mL bacteriostatic water to a 5 mg vial

    Aim the stream against the glass wall, not directly onto the powder. Swirl gently until dissolved. Concentration: 5000 mcg per mL.

  2. 2
    Draw your dose using a 100-unit insulin syringe

    Beginner (2000 mcg): draw to the 40-unit mark. Moderate (2500 mcg): draw to the 50-unit mark. Aggressive (5000 mcg): draw to the 100-unit mark (full syringe). For a 10 mg vial reconstituted with 1 mL BAC water (10,000 mcg/mL), beginner dose is 20 units.

  3. 3
    Inject subcutaneously

    Pinch a fold of skin on the abdomen or thigh. Insert a 27 to 29 gauge, 0.5 inch needle at a 45-degree angle. Push the plunger slowly.

  4. 4
    Rotate injection sites each time

    Abdomen left, abdomen right, thigh left, thigh right. Injection site does not need to be near the injury; TB-500 distributes systemically.

  5. 5
    Timing: inject any time of day

    No fasting requirement. Space injections 3 to 4 days apart during loading (e.g., Monday and Thursday).

  6. 6
    Loading phase: 2 injections per week for 4 to 6 weeks

    Maintenance phase: 1 injection per week. Reload at full loading dose and frequency if a new injury occurs.

  7. 7
    Step 7

    Storage after reconstitution: refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Use within 3 to 4 weeks. Lyophilized (unreconstituted) vials are stable refrigerated for up to 24 months.

Mixing your own vial? Use the TB-500 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

TB-500 Stacking Protocols

Works With

Avoid

Anti-VEGF therapies (bevacizumab, ranibizumab, aflibercept)

TB-500 upregulates VEGF 2.5–3.8-fold. Anti-VEGF agents directly antagonize this mechanism. Concurrent use creates direct pharmacodynamic opposition and defeats the purpose of TB-500.

Do not combine
High-dose chronic NSAIDs

Chronic high-dose NSAIDs may blunt TB-500 angiogenic signaling through prostaglandin pathway suppression. Short-term/low-dose NSAID use for acute pain management is unlikely to be clinically significant.

Anticoagulants (warfarin, heparin, DOACs)

TB-500 promotes angiogenesis at healing sites. Concurrent anticoagulation may increase bleeding risk at sites of active new vascular formation.

Immunosuppressants (cyclosporine, tacrolimus, mycophenolate)

TB-500 modulates immune cell migration and angiogenic pathways. Effect of combining with systemic immunosuppression is unknown; potential for altered immune regulation.

How much does TB-500 cost?

Typical price

$5.25 to $8.00 per mg

Typical $6.50

Middle half of 104 US prices for 10 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Listed as withdrawn from FDA Category 2 as of April 22, 2026. PCAC discussed it on July 23, 2026. No 503A bulks rule has issued, so US 503A compounding pharmacies cannot use it today.

Pricing updated 2026-04-09

TB-500 Side Effects

No published study has given TB-500 itself to people, and FDA's July 2026 briefing found no human exposure data for it by any route. Two published phase 1 trials gave the full 43-amino-acid thymosin beta-4 intravenously instead. Ruff 2010 enrolled 40 healthy volunteers [5]; a 2021 Chinese study enrolled 54 single-dose and 30 multiple-dose volunteers [2]. Safety data for the fragment comes almost entirely from community self-reports.

Injection site reactions are the most frequently reported problem. Redness, swelling, and tenderness at the injection site appear in a large percentage of users. Rotating between abdomen and thigh reduces local accumulation. Blistering, progressive swelling, or spreading warmth beyond the injection site is abnormal and requires stopping immediately.

Fatigue and lethargy during the loading phase (weeks 1 to 2) rank second. Community reports describe this as the most common early side effect at doses of 4 to 5 mg per week. It usually resolves by week 3 without dose adjustment. If fatigue is debilitating, stepping down to 2 mg twice weekly is the standard community recommendation.

Headache during loading is common and typically follows the same resolution pattern as fatigue. Nausea is less frequent.

Rare but serious reactions include fever above 100.4 degrees F, injection site blistering, skin rash, hives, and muscle aches. Any of these require stopping the protocol and seeking medical evaluation.

The unresolved long-term concern is oncogenic risk. TB-500 is pro-angiogenic. It promotes new blood vessel formation. In the presence of occult tumor tissue, this mechanism could theoretically support vascularization and tumor growth. Active cancer or personal cancer history is an absolute contraindication at any dose. Baseline age-appropriate cancer screening (PSA, mammogram, colonoscopy as applicable) is recommended before starting, particularly for anyone over 40.

TB-500 is WADA prohibited (S2: Growth Factors) in and out of competition. A 4-year ban was issued in 2024 for documented use. DoD personnel face the same restriction.

Pregnancy and breastfeeding: no safety data exists. Do not use.

Common Issues & Solutions

No results after 3–4 weeks: Most common cause is skipping the loading phase. Single weekly injections at maintenance dose from the start are insufficient: TB-500 requires 2×/week loading to establish adequate tissue-level concentrations. Restart with a proper 6-week loading phase.

Fatigue and lethargy during loading: Expected in weeks 1–2 at 4–5 mg/week+. Usually self-resolves by week 3. If debilitating, reduce to 2 mg 2×/week and reassess. Do not abandon the loading phase for mild fatigue: this is the most common cause of undertreatment.

Continuing injurious activity during protocol: The most cited reason for poor healing outcomes in community reports. TB-500 accelerates tissue repair but does not protect against re-injury from continued loading of the damaged structure. Relative rest of the injured tissue is strongly recommended.

Injection site reactions: Mild redness and tenderness are expected. Rotating sites (abdomen, thigh, alternating sides) minimizes local accumulation. Blistering, progressive swelling, spreading redness, or warmth extending beyond the injection site warrants stopping and medical evaluation for infection.

Sourcing and quality concerns: TB-500 is listed as withdrawn from FDA Category 2 (FDA page current as of April 22, 2026), but no FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today (PCAC discussed it July 23, 2026). All available supply is gray-market research-grade product with no regulatory quality assurance. Endotoxin contamination, peptide mislabeling, and significant underdosing are documented community concerns. Price does not measure purity. Only an independent lab test of a specific batch, covering HPLC purity and endotoxin, shows what a vial actually holds.

Ask AI about this page

Ask AI for a second opinion on TB-500 dosing and side effects

Contraindications

  • Active cancer or personal history of cancer: TB-500 promotes angiogenesis, which may support tumor vascularization and growth
  • Pregnancy or breastfeeding: no safety data available in pregnant or lactating individuals
  • Active systemic infections: enhanced cell migration could theoretically spread pathogens
  • Known hypersensitivity to thymosin beta-4 or any component of the formulation

Drug Interactions

  • Anticoagulants (warfarin, heparin, DOACs): TB-500 promotes angiogenesis and may increase bleeding risk at healing sites
  • Other angiogenic healing peptides (BPC-157): additive angiogenic effects; monitor closely when stacking, though this combination is commonly used
  • Immunosuppressants: TB-500 modulates immune cell migration; effect on immunosuppressive therapy is unknown
  • Anti-VEGF therapies (bevacizumab): directly opposes TB-500 mechanism; concurrent use is contraindicated
  • Chronic high-dose NSAIDs may blunt TB-500 angiogenic signaling through prostaglandin pathway suppression. Short-term/low-dose NSAID use for acute pain management is unlikely to be clinically significant.

Product Quality

Recommended Monitoring

TestWhenTarget
Baseline cancer screeningBefore starting, especially for anyone over 40 or with family history of cancerAge-appropriate cancer screening current (PSA, mammogram, colonoscopy as applicable); no active malignancy
CBC and CMP (comprehensive metabolic panel)Baseline before starting; optional recheck at 6–8 weeks for longer protocolsNot listed
Injection site self-assessmentEach injection: visual inspection and palpation before and afterMinor transient redness and mild tenderness are expected and normal; spreading, progressive, or blistering reactions are abnormal and require stopping
Baseline cancer screening

TB-500 is pro-angiogenic: it promotes new blood vessel formation. In the presence of occult or undiagnosed tumor tissue, this mechanism could theoretically support vascularization and tumor growth. Active or historical cancer is an absolute contraindication.

CBC and CMP (comprehensive metabolic panel)

No specific TB-500 safety biomarkers exist. CBC/CMP as general health baseline to detect subclinical conditions that would be contraindications (active infection, hepatic/renal impairment).

Injection site self-assessment

Early detection of infection (spreading redness, warmth, induration beyond expected local reaction) or allergic response (hives, blistering, spreading rash)

TB-500 Before and After

Weeks 1-2

Loading phase begins: 2x/week at full dose. Mild systemic effects may include temporary lethargy or headache. Inflammation reduction may begin within days.

Weeks 3-4

Loading phase continues. Noticeable improvement in pain levels, flexibility, and range of motion around injured areas. New blood vessel formation (angiogenesis) accelerates tissue repair.

Weeks 5-6

End of loading phase. Significant healing progress in soft tissue injuries. Many users report substantially reduced pain and improved function.

Weeks 7+

Transition to maintenance: 1,000-2,000 mcg once weekly (community reports). Continued healing support. Reload at full dose if a new injury occurs.

What to Expect

Weeks 1 to 2: Loading begins at full dose twice weekly. Angiogenic signaling kicks in at the cellular level, with VEGF upregulation and actin sequestration starting to draw immune and endothelial cells toward injury sites. You won't feel much improvement in the injury itself yet. Fatigue, mild headache, and injection site tenderness are the most common early complaints.

Weeks 3 to 4: This is usually when TB-500 starts to prove itself. Most users describe noticeable improvement in pain levels, flexibility, and range of motion. Tendon and ligament injuries tend to show the clearest early response. Loading phase side effects typically fade by week 3.

Weeks 5 to 6: Peak loading effect. Accumulated angiogenesis and tissue remodeling from the loading phase produce the most visible healing progress. Fibrosis suppression contributes to better tissue quality and less scar formation. Many users report near-full functional return by the end of loading.

Weeks 7 to 12: Transition to maintenance at 1,000-2,000 mcg once weekly (community reports). Continued gradual improvement for complex injuries. Some users stop at week 8 if the injury is resolved; others carry maintenance to week 12 for more severe damage. Side effects at maintenance dose are typically absent.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

Angiogenic signaling initiates: VEGF upregulation and actin sequestration begin facilitating immune and endothelial cell migration to injury sites. No measurable structural tissue changes at this timescale.

Community

Little to no noticeable change in injury status. Some users report a general sense of reduced systemic inflammation. Fatigue and mild headache most commonly reported.

Weeks 3–4
Science

Angiogenesis and collagen deposition underway. New capillary formation at injury site supports oxygen and nutrient delivery. Anti-inflammatory signaling reduces pro-inflammatory cytokines.

Community

Most users report noticeable improvement in pain, flexibility, and range of motion. Tendon and ligament injuries show the clearest early response at this stage. This is typically the first point where TB-500 is subjectively validated.

Weeks 5–6
Science

Accumulated angiogenic and tissue remodeling effects from loading. Fibrosis inhibition via myofibroblast differentiation suppression contributes to improved tissue quality and reduced scar formation.

Community

Significant healing progress for most soft tissue injuries. Many users report substantially reduced pain and improved functional capacity. Some report near-full return to training.

Weeks 7–12
Science

Maintenance dosing preserves angiogenic stimulus at lower intensity. Tissue remodeling continues; collagen organization matures toward functional architecture.

Community

Continued gradual improvement. Some cycle off at week 8 if injury is resolved; others continue to week 12 for complex injuries. Maintenance dosing (1,000-2,000 mcg once weekly) is well-tolerated with minimal side effects.

Pharmacokinetics

Half-Life
5h
Bioavailability
SC: not established in humans
Tmax
Not characterized in humans
Data Confidence
low

Source: No human PK study of TB-500 exists: FDA's July 2026 PCAC briefing found no human exposure data by any route. In horses given 10 mg SC, plasma TB-500 peaked at 1 to 2 h and was unquantifiable by 6 to 10 h (Ho 2012, cited by FDA). The ~5 h figure has no published source

Pharmacokinetics: Active Dose Over Time

t½ = ~5 hours (estimated, never measured in humans)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
7
Molecular Weight
889.02 Da
Sequence
LKKTETQ
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider TB-500

  • Athletes recovering from soft tissue injuries (tendons, ligaments, muscle tears)
  • Post-surgical patients seeking accelerated wound healing
  • Individuals with chronic tendinopathy or repetitive strain injuries
  • Older adults with impaired healing capacity
  • People recovering from traumatic brain injury (TBI): preclinical evidence only
  • Those with fibrotic conditions seeking to reduce scar tissue formation

Related Peptides

What Changed for TB-500

  1. Evidence

    Corrected Oct 15, 2026: TB-500's side effects no longer cite one 'only' phase 1 trial; no study has given TB-500 itself to people, per FDA's TB-500 briefing.

    Before: Called PMID 34346165 the only published phase 1, in 36 volunteers, and said TB-500 had never completed a phase 2 or 3 trial After: No published study has given TB-500 to people; two phase 1 trials of full-length thymosin beta-4 (40 volunteers, PMID 20536472; 54 plus 30, PMID 34346165)

    What this does not mean: No new study was published. Two phase 1 trials (Ruff 2010, PMID 20536472; Wang 2021, PMID 34346165) gave intravenous full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment.

    Source: FDA, Pharmacy Compounding Advisory Committee briefing document for TB-500-related bulk drug substances, July 23-24, 2026 (memo dated May 15, 2026): 'FDA is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA' (p. 32) (opens in a new tab) · Saved copy

  2. Regulatory

    PCAC backed TB-500 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  3. Evidence

    In rats, BPC-157 plus TB-500 gave no added Achilles tendon benefit over either peptide alone, per Jt Dis Relat Surg, Jul 23, 2026.

    What this does not mean: One small rat study: 8 rats per group, 4 weeks of intraperitoneal injections. It did not test people or the pre-mixed vial, and it does not show the stack slows healing.

    Also covers: Wolverine Stack (BPC-157 + TB-500), BPC-157

    Source: Joint Diseases and Related Surgery 2026, BPC-157 and TB-500 on Achilles tendon healing in rats (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  4. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Also covers: BPC-157, KPV, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 9, 202612 Citations

References

  1. [1]Thymosin beta 4 accelerates wound healing (Malinda et al., 1999: establishes reepithelialization baseline) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]First-in-human phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteers (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Thymosin beta4 is cardioprotective after myocardial infarction (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study (Biçer et al., Jt Dis Relat Surg 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers (Ruff et al., Ann N Y Acad Sci 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C, stable up to 24 months
After Reconstitution
Refrigerate, use within 3-4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Loading phase: 2,000-2,500 mcg subcutaneous, twice per week for 4-6 weeks. Maintenance: 1,000-2,000 mcg once weekly (community reports). The loading phase front-loads systemic thymosin beta-4 levels. Some community protocols run 5,000 mcg twice weekly for acute injuries.

Community reports from hundreds of users most commonly mention temporary lethargy, mild headache, and a "healing flare" (temporary increase in pain or inflammation at the injury site during weeks 1-2). This flare typically resolves by week 3 and may indicate increased repair activity. No formal human safety data exists for the fragment itself.

TB-500 is a synthetic version of the active region (amino acids 17-23) of thymosin beta-4. It promotes actin polymerization, which allows cells to migrate toward damaged tissue. The peptide also upregulates anti-inflammatory cytokines and promotes new blood vessel formation. Its 7-10 day functional activity window explains why less frequent dosing is effective.

Most users report noticeable improvement in soft tissue injuries by weeks 2-3 of the loading phase. Tendon and ligament injuries may take 4-8 weeks to show clear progress. The healing timeline depends heavily on injury severity, location, and whether you're combining TB-500 with BPC-157 or other peptides.

No. TB-500 has preclinical status. Most published research comes from equine veterinary studies where it showed accelerated tendon repair. No published study has given TB-500 itself to people. TB-500 was on the FDA Category 2 bulk drug substance list from 2024 until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed it on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today.